Q1. Which of the following best describes the mechanism of action of lenacapavir, the HIV-prevention drug launched in Zimbabwe in 2026?
Explanation
Lenacapavir is a capsid inhibitor — it disrupts the protein shell (capsid) of HIV, preventing the virus from replicating inside host cells. It is not a reverse transcriptase inhibitor (Option A) or a monoclonal antibody (Option D). Its novel mechanism and twice-yearly dosing made it a breakthrough HIV prevention tool.
